Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Journal: Journal of drugs in dermatology : JDD
Published: August 13, 2015
Prevalence of the metabolic syndrome in children with psoriatic disease.
Journal: Pediatric dermatology
Published: September 11, 2013
A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
Journal: Journal of drugs in dermatology : JDD
Published: March 08, 2012
Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.
Journal: The Journal of dermatological treatment
Published: March 07, 2012
Association between pediatric psoriasis and the metabolic syndrome.
Journal: Journal of the American Academy of Dermatology
Published: October 06, 2011
Showing 1-5 of 5
Last Updated: 09/26/2026